Abstract: Disclosed is a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction. A pH-sensitive and bioreducible polymer contains (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages. The and to a pharmaceutical composition containing the polymer-virus complex. Also disclosed are a pharmaceutical composition containing the pH-sensitive and bioreducible polymer-virus complex and methods for treating cancer in a subject, employing the composition.

Abstract: A cell sheet for gene delivery is disclosed. Unlike conventional cell sheets for tissue regeneration, the disclosed cell sheet can be used as a local gene delivery system. Particularly when a virus is used as a gene delivery system, the virus can be proliferated within the cell sheet and acts topically within a therapeutic region. Thus, the cell sheet is superior in the prevention or treatment of cancer, the prevention of cancer recurrence or cancer metastasis, particularly the treatment of multifocal tumor even though the virus dose is remarkably lowered compared to the systemic administration or intratumoral injection of the virus.

Abstract: The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.

Abstract: The present invention relates to a novel gene delivery system and recombinant adenovirus including the relaxin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition including the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.

Abstract: The present invention relates to a technique for effective intranasal delivery to the brain. More specifically, the present invention is used for diagnosing, preventing or treating central nervous system encephalopathy, neurodegenerative diseases or brain tumor by effectively delivering to the brain a pH-responsive and bioreducible PPA polymer, which can be used as a drug carrier, by means of nasal administration.

Abstract: The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.

Abstract: An oncolytic adenovirus co-expressing interleukin (IL-12) and shVEGF and a composition for enhancing an anticancer effect are disclosed. The inventors confirmed that, when VEGF suppression and IL-12 expression are co-expressed in immunocompetent murine melanoma or kidney cancer models, an immune function is restored and an anticancer effect is improved. Particularly, it has been revealed that such an improved anticancer effect is associated with an increase in anticancer immunity, an increase in Thl cytokines and prevention of tumor-induced thymic atrophy, and therefore the applicability of a gene delivery system co-expressing IL-12 and shVEGF to cancer gene therapy was identified for the first time.

Abstract: The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.

Abstract: Disclosed is a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction. A pH-sensitive and bioreducible polymer contains (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages. The and to a pharmaceutical composition containing the polymer-virus complex. Also disclosed are a pharmaceutical composition containing the pH-sensitive and bioreducible polymer-virus complex and methods for treating cancer in a subject, employing the composition.

Abstract: The present invention relates to an adenovirus complex which can be utilized for gene delivery and gene therapy by targeting neurotensin receptors. The complex of the present invention has an excellent antitumor effect because of a high intracellular gene transfer efficiency and target specificity by neurotensin receptor-specific binding, has little hepatotoxicity and immunogenicity, forms a stable complex, has low immunogenicity, and thus has a low loss in blood even in an in vivo environment. Therefore, the complex of the present invention can be effectively used for gene therapy.

Abstract: The present invention relates to an oncolytic adenovirus capable of co-expressing interleukin-12 and a C-met-inhibiting oligonucleotide; and an antitumor immune-boosting composition and anticancer composition comprising the oncolytic adenovirus. The present invention has first identified an adenovirus system having simultaneous effects of IL-12 expression and C-met inhibition in cancer gene treatment. The adenovirus system of the present invention is capable of inhibiting C-met while expressing interleukin-12, thereby restoring immune functions in a tumor environment to enhance anticancer effects such as the inhibition of tumor recurrence and tumor growth and to inhibit tumor migration. Accordingly, the adenovirus system of the present invention can be effectively used in the treatment of cancer.

Abstract: The present invention relates to a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction, to a pH-sensitive and bioreducible polymer, and to a pharmaceutical composition containing the polymer-virus complex.

Abstract: The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.

Abstract: The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.

Abstract: A cell sheet for gene delivery is disclosed. Unlike conventional cell sheets for tissue regeneration, the disclosed cell sheet can be used as a local gene delivery system. Particularly when a virus is used as a gene delivery system, the virus can be proliferated within the cell sheet and acts topically within a therapeutic region. Thus, the cell sheet is superior in the prevention or treatment of cancer, the prevention of cancer recurrence or cancer metastasis, particularly the treatment of multifocal tumor even though the virus dose is remarkably lowered compared to the systemic administration or intratumoral injection of the virus.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a keloid disease or scars. The inventors of the present invention discovered that mortalin expression inhibition and the interaction between mortalin and p53 may be new targets for keloid treatment. In the present invention, apoptosis and an anti-fibrotic effect were verified by preparing a mortalin-specific shRNA (dE1-RGD/GFP/shMOT) and injecting same in a keloid spheroid. Thus, by reducing ECM expression and inducing apoptosis in a keloid spheroid, mortalin knockdown may be very usefully employed for keloid treatment.

Abstract: The present invention relates to a complex of an antitumor adenovirus coated with ErbB-PEG-PAMAM and the use thereof. When using the complex of the present invention, a tumor cell-specific gene transfer effect by an excellent tumor cell infiltration ability is excellent, hepatotoxicity is low, a blood flow retention time is prolonged. Thus, the complex of the present invention can be used as a pharmaceutical composition for the treatment of a tumor and a gene therapy agent which can be administered systemically.

Abstract: The present invention relates to an intranasal pharmaceutical composition comprising anticancer drug-containing nanoparticles for treating brain diseases. More specifically, the anticancer drug-containing nanoparticles are nasally administered to deliver the anticancer drug to only brain cells, thereby increasing therapeutic effects on brain tumor and reducing cytotoxicity to normal cells by an organic solvent used in the conventional delivery of the anticancer drug.

Abstract: The present invention relates to a composition for intracellular delivery containing an adenovirus protein VI-derived peptide and an anti-cancer pharmaceutical composition containing the same. According to the present invention, the use of the peptide or peptide-polymer composite of the present invention improves intracellular delivery efficiency of a nucleic acid, a peptide, a poly-peptide, an antibody, a chemical material, or a virus. Therefore, the peptide or peptide-polymer composite of the present invention can be favorably used as an intracellular delivery system for various therapeutics.

Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.